U.S. markets open in 8 hours
  • S&P Futures

    4,617.00
    +27.00 (+0.59%)
     
  • Dow Futures

    35,402.00
    +190.00 (+0.54%)
     
  • Nasdaq Futures

    15,948.75
    +106.00 (+0.67%)
     
  • Russell 2000 Futures

    2,220.70
    +17.10 (+0.78%)
     
  • Crude Oil

    70.57
    +1.08 (+1.55%)
     
  • Gold

    1,782.20
    +2.70 (+0.15%)
     
  • Silver

    22.45
    +0.19 (+0.86%)
     
  • EUR/USD

    1.1298
    +0.0011 (+0.10%)
     
  • 10-Yr Bond

    1.4340
    0.0000 (0.00%)
     
  • Vix

    27.18
    -3.49 (-11.38%)
     
  • GBP/USD

    1.3287
    +0.0027 (+0.20%)
     
  • USD/JPY

    113.7270
    +0.2370 (+0.21%)
     
  • BTC-USD

    51,143.38
    +2,420.54 (+4.97%)
     
  • CMC Crypto 200

    1,319.15
    +58.99 (+4.68%)
     
  • FTSE 100

    7,232.28
    +109.96 (+1.54%)
     
  • Nikkei 225

    28,455.60
    +528.23 (+1.89%)
     

Why Did the FDA Reject Rigel's EUA Application for Its COVID-19 Therapy?

·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Rigel Pharmaceuticals (NASDAQ: RIGL) recently received a thumbs-down from the Food and Drug Administration for an EUA filing for its COVID therapeutic candidate. In this Motley Fool Live video recorded on Aug. 18, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why the FDA turned down an EUA for Rigel's experimental COVID therapy.